Uveoscleral outflow - A review

Experimental Eye Research

Volumn 88, Issue 4, 2009, Pages 760-768

  Alm, Albert ^a   Nilsson, Siv F E ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

aqueous humor dynamics; normal values, physiology; pharmacology; uveoscleral flow

Indexed keywords

ADRENALIN; APRACLONIDINE; ATROPINE; BETA 2 ADRENERGIC RECEPTOR; BIMATOPROST; BRIMONIDINE; INDOMETACIN; ISOPRENALINE; LATANOPROST; PHYSOSTIGMINE; PILOCARPINE; PROSTAGLANDIN; PROSTAGLANDIN F2 ALPHA; SALBUTAMOL; TERBUTALINE;

AQUEOUS HUMOR; CILIARY MUSCLE; DRUG MECHANISM; DRUG POTENTIATION; EXTRACELLULAR MATRIX; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NONHUMAN; PRESSURE GRADIENT; PRIORITY JOURNAL; REVIEW; SCHLEMM CANAL; SCLERA; SPECIES DIFFERENCE; UVEA; UVEITIS; UVEOSCLERAL OUTFLOW; VISUAL SYSTEM FUNCTION;

ADRENERGIC AGENTS; ADULT; AGED, 80 AND OVER; AGING; ANIMALS; AQUEOUS HUMOR; CHOLINERGIC AGENTS; HUMANS; MACACA FASCICULARIS; PROSTAGLANDINS; SCLERA; SPECIES SPECIFICITY; UVEA;

EID: 64249083215     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2008.12.012     Document Type: Review

References (88)

1. Alm A., and Villumsen J. PhXA34 - a potent ocular hypotensive drug. A study on effect-side effect relationship and on aqueous humor dynamics in healthy volunteers. Arch. Ophthalmol 109 (1991) 1564-1568
2. Anderson O.A., Jackson T.L., Singh J.K., Hussain A.A., and Marshall J. Human transscleral albumin permeability and the effect of topographical location and donor age. Invest. Ophthalmol. Vis. Sci. 49 (2008) 4041-4045
3. 3H-labelled dextran. Am. J. Vet. Res. 46 (1985) 84-88
4. Becker B. The decline in aqueous secretion and outflow facility with age. Am. J. Ophthalmol 46 (1958) 731-736
5. Bill A. The aqueous humor drainage mechanism in the cynomolgus monkey (Macaca irus) with evidence for unconventional routes. Invest. Ophthalmol 4 (1965) 911-919
6. Bill A., and Hellsing K. Production and drainage of aqueous humor in the cynomolgus money (Macaca irus). Invest. Ophthalmol 4 (1965) 920-926
7. Bill A. Conventional and uveo-scleral drainage of aqueous humour in the cynomolgus monkey (Macaca irus) at normal and high intraocular pressures. Exp. Eye Res. 5 (1966) 45-54
8. Bill A. The routes for bulk drainage of aqueous humour in the vervet monkey (Cercopithecus ethiops). Exp. Eye Res. 5 (1966) 55-57
9. Bill A. Formation and drainage of aqueous humour in cats. Exp. Eye Res. 5 (1966) 185-190
10. Bill A. The routes for bulk drainage of aqueous humour in rabbits with and without cyclodialysis. Doc. Ophthalmol 20 (1966) 157-169
11. Bill A. Further studies on the influence of the intraocular pressure on aqueous humor dynamics in cynomolgus monkeys. Invest. Ophthalmol. Vis. Sci. 6 (1967) 364-372
12. Bill A. Effects of atropine and pilocarpine on aqueous humour dynamics in cynomolgus monkeys (Macaca irus). Exp. Eye Res. 6 (1967) 120-125
13. Bill A. Early Effects of epinephrine on aqueous humor dynamics in vervet monkeys (Cercopithecus ethiops). Exp. Eye Res. 8 (1969) 35-43
14. Bill A. Effects of norepinephrine, isoproterenol and sympathetic stimulation on aqueous humour dynamics in vervet monkeys. Exp. Eye Res. 10 (1970) 31-46
15. Bill A. Scanning electron microscopic studies of the canal of Schlemm. Exp. Eye Res. 10 (1970) 214-218
16. Bill A. Aqueous humour dynamics in monkeys (Macaca irus and Cercopithecus ethiops). Exp. Eye Res. 11 (1971) 195-206
17. Bill A. Basic physiology of the drainage of aqueous humor. Exp. Eye Res. Suppl (1977) 291-304
18. Bill A. Physiology of the outflow mechanism. In: Drance S.M. (Ed). Applied Pharmacology in the Medical Treatment of Glaucoma (1984), Grune and Stratton, Inc., Orlando 111-133
19. Bill A., and Phillips C.I. Uveoscleral drainage of aqueous humour in human eyes. Exp. Eye Res. 12 (1971) 275-281
20. Brubaker R.F. Flow of aqueous flow in humans. The Friedenwald lecture. Invest. Ophthalmol. Vis. Sci. 32 (1991) 3145-3166
21. Brubaker R.F. Mechanism of action of bimatoprost (Lumigan). Surv. Ophthalmol 45 Suppl 4 (2001) S347-S351
22. Brubaker R.F., Schoff E.O., Nau C.B., Carpenter S.P., Chen K., and Vandenburgh A.M. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am. J. Ophthalmol 131 (2001) 19-24
23. Camras C.B., Feldman S.G., Podos S.M., Christensen R.E., Gardner S.K., and Fazio D.T. Inhibition of the epinephrine-induced reduction of intraocular pressure by systemic indomethacin in humans. Am. J. Ophthalmol 100 (1985) 169-175
24. Camras C.B., Podos S.M., Rosenthal J.S., Lee P.Y., and Severin C.H. Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. I. Aqueous humor dynamics. Invest. Ophthalmol. Vis. Sci. 28 (1987) 463-469
25. Coakes R.L., and Siah P.B. Effects of adrenergic drugs on aqueous humour dynamics in the normal human eye. I. Salbutamol. Br. J. Ophthalmol 68 (1984) 393-397
26. Crawford K., and Kaufman P.L. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. Arch. Ophthalmol 105 (1987) 1112-1116
27. Crawford K., Kaufman P.L., and Gabelt B.T. Effects of topical PGF2 alpha on aqueous humor dynamics in cynomolgus monkeys. Curr. Eye Res. 6 (1987) 1035-1044
28. Crawford K.S., and Kaufman P.L. Dose-related effects of prostaglandin F2 alpha isopropylester on intraocular pressure, refraction, and pupil diameter in monkeys. Invest. Ophthalmol. Vis. Sci. 32 (1991) 510-519
29. Croft M.A., Oyen M.J., Gange S.J., Fisher M.R., and Kaufman P.L. Aging effects on accommodation and outflow facility responses to pilocarpine in humans. Arch. Ophthalmol 114 (1996) 586-592
30. Crowston J.G., Lindsey J.D., Aihara M., and Weinreb R.N. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest. Ophthalmol. Vis. Sci. 45 (2004) 3555-3559
31. Crowston J.G., Lindsey J.D., Morris C.A., Wheeler L., Medeiros F.A., and Weinreb R.N. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest. Ophthalmol. Vis. Sci. 46 (2005) 4571-4577
32. Emi K., Pederson J.E., and Toris C.B. Hydrostatic pressure of the suprachoroidal space. Invest. Ophthalmol. Vis. Sci. 30 (1989) 233-238
33. Fatt I., and Hedbys B. Flow of water in the sclera. Exp. Eye Res. 10 (1970) 243-249
34. Friström B., and Nilsson S.E. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch. Ophthalmol 111 (1993) 662-665
35. Gaasterland D., Kupfer C., Milton R., Ross K., McCain L., and MacLellan H. Studies of aqueous humour dynamics in man. VI. Effect of age upon parameters of intraocular pressure in normal human eyes. Exp. Eye Res. 26 (1978) 651-656
36. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 49 (1989) 389-402
37. Gabelt B.T., Crawford K., and Kaufman P.L. Outflow facility and its response to pilocarpine decline in aging rhesus monkeys. Arch. Ophthalmol 109 (1991) 879-882
38. Gabelt B.T., and Kaufman P.L. Changes in aqueous humor dynamics with age and glaucoma. Prog. Retin. Eye Res. 24 (2005) 612-637
39. Gupta, N., Patel, M., Ly, T., Gümüs, E., Johnston, M.G., Armstrong, D., Yücel, Y., 2008. Evidence of a new uveolymphatic outflow pathway in human and sheep: implications for aqueous humor drainage and glaucoma. Invest. Ophthalmol. Vis. Sci. 49, E-Abstract 2879.
40. Hedman K., and Alm A. A pooled-data analysis of three randomized, double-masked six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur. J. Ophthalmol 10 (2000) 95-104
41. Inomata H., Bill A., and Smelser G.K. Unconventional routes of aqueous humor outflow in cynomolgus monkey (Macaca irus). Am. J. Ophthalmol 73 (1972) 893-907
42. Inomata H., and Bill A. Exit sites of uveoscleral flow of aqueous humor in cynomolgus monkey eyes. Exp. Eye Res. 25 (1977) 113-118
43. Jackson T.L., Hussain A., Hodgetts A., Morley A.M.S., Hillenkamp J., Sullivan P.M., and Marshall J. Human scleral hydraulic conductivity: age-related changes, topographical variation, and potential scleral outflow facility. Invest. Ophthalmol 47 (2006) 4942-4946
44. Johnson T.V., Fan S., Camras C.B., and Toris C.B. Aqueous humor dynamics in exfoliation syndrome. Arch. Ophthalmol 126 (2008) 914-920
45. Kaufman P.L., and Bárány E.H. Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 15 (1976) 793-807
46. Krohn J., and Bertelsen T. Corrosion casts of the suprachoroidal space and uveoscleral drainage routes in the human eye. Acta Ophthalmol. Scand 75 (1997) 32-35
47. Krohn J., and Bertelsen T. Light microscopy of uveoscleral drainage routes after gelatine injections into the suprachoroidal space. Acta Ophthalmol. Scand 76 (1998) 521-527
48. Lim K.S., Nau C.B., O'Byrne M.M., Hodge D.O., Toris C.B., McLaren J.W., and Johnson D.H. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 115 (2008) 790-795
49. Lindén C., Nuija E., and Alm A. Effects on intraocular pressure restoration and blood aqueous barrier after long-term treatment with latanoprost in POAG and ocular hypertension. Br. J. Ophthalmol 81 (1997) 370-372
50. Lindén C., and Alm A. Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes. Arch. Ophthalmol 115 (1997) 857-861
51. Lindsey J.D., To H.D., and Weinreb R.N. Induction of c-Fos by prostaglandin F2a in human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 35 (1994) 242-250
52. Lindsey J.D., Kashiwagi K., Boyle D., Kashiwagi F., Firestein G.S., and Weinreb R.N. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr. Eye Res. 15 (1996) 869-875
53. Lütjen-Drecoll E., and Tamm E. Cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp. Eye Res. 47 (1988) 761-769
54. Mäepea O., and Bill A. The pressures in the episcleral veins, Schlemm's canal and the trabecular meshwork in monkeys: effects of changes in intraocular pressure. Exp. Eye Res. 49 (1989) 645-663
55. Mäepea O., and Bill A. Pressures in the juxtacanalicular tissue and Schlemm's canal in monkeys. Exp. Eye Res. 54 (1992) 879-883
56. Nilsson S.F., and Bill A. Vasoactive intestinal polypeptide (VIP): effects in the eye and on regional blood flows. Acta Physiol. Scand 121 (1984) 385-392
57. Nilsson S.F.E., Sperber G.O., and Bill A. Effects of vasoactive intestinal polypeptide (VIP) on intraocular pressure, facility of outflow and formation of aqueous humor in the monkey. Exp. Eye Res. 43 (1986) 849-857
58. 2α-1-isopropylester in the cynomolgus monkey. Exp. Eye Res. 48 (1989) 707-716
59. Nilsson S.F.E., Maepea O., Samuelsson M., and Bill A. Effects of timolol on terbutaline- and VIP-stimulated aqueous humor flow in the cynomolgus monkey. Curr. Eye Res. 9 (1990) 863-872
60. Nilsson S.F.E. PACAP-27 and PACAP-38: vascular effects in the eye and some other tissues in the rabbit. Eur. J. Pharmacol 253 (1994) 17-25
61. Nilsson, S.F.E., Bill, A., 1994. Physiology and neurophysiology of aqueous humor inflow and outflow, in: Kaufman, P.L., Mittag, T.W. (Eds.), Glaucoma (ed. P.L. Kaufman, T.W. Mittag). Mosby-Year Book Europe Ltd., 1994.
62. Nilsson S.F.E., Drecoll E., Lütjen-Drecoll E., Toris C.B., Krauss A.H., Kharlamb A., Nieves A., Guerra T., and Woodward D.F. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 47 (2006) 4042-4049
63. Ocklind A., Lake S., Wentzel P., Nistér M., and Stjernschantz J. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest. Ophthalmol. Vis. Sci. 37 (1996) 716-726
64. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp. Eye Res. 67 (1998) 179-191
65. Pederson J.E., and Toris C.B. Uveoscleral outflow: diffusion or flow?. Invest. Ophthalmol. Vis. Sci. 28 (1987) 1022-1024
66. Poyer J.F., Gabelt B., and Kaufman P.L. The effect of topical PGF2 alpha on uveoscleral outflow and outflow facility in the rabbit eye. Exp. Eye Res. 54 (1992) 277-283
67. Poyer J.F., Millar C., and Kaufman P.L. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest. Ophthalmol. Vis. Sci. 36 (1995) 2461-2465
68. Sagara T., Gaton D.D., Lindsey J.D., Gabelt B.T., Kaufman P.L., and Weinreb R.N. Topical prostaglandin F2a treatment reduces collagen types I, III and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol 117 (1999) 794-801
69. Schenker H.I., Yablonski M.E., Podos S.M., and Linder L. Fluorophotometric study of epinephrine and timolol in human subjects. Arch. Ophthalmol 99 (1981) 1212-1216
70. Sperber G.O., and Bill A. A method for near-continuous determination of aqueous humor flow; effects of anaesthetics, temperature and indomethacin. Exp. Eye Res. 39 (1984) 435-453
71. Stjernschantz J., Selén G., Sjöquist B., and Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2a analogue. Adv. Prostaglandin Thromboxane Leukot. Res. 23 (1995) 513-518
72. Stjernschantz J., Selén G., Ocklind A., and Resul B. Effects of latanoprost and related prostaglandin analogues. In: Alm A., and Weinreb R.N. (Eds). Uveoscleral Outflow. Biology and Clinical Aspects (1998), Mosby-Wolfe Medical Communications, London 57-72
73. Stjernschantz J.W. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 42 (2001) 1134-1145
74. Suguro K., Toris C.B., and Pederson J.E. Uveoscleral outflow following cyclodialysis in the monkey eye using a fluorescent tracer. Invest. Ophthalmol. Vis. Sci. 26 (1985) 810-813
75. Tamm S., Tamm E., and Rohen J.W. Age-related changes in the human ciliary muscle. A quantitative morphologic study. Mech. Ageing Dev. 62 (1992) 209-221
76. Toris C.B., and Pederson J.E. Effect of intraocular pressure on uveoscleral outflow following cyclodialysis in the monkey eye. Invest. Ophthalmol. Vis. Sci. 26 (1985) 1745-1749
77. Toris C.B., and Pederson J.E. Aqueous humor dynamics in experimental iridocyclitis. Invest. Ophthalmol. Vis. Sci. 28 (1987) 477-481
78. Toris C.B., Camras C.B., and Yablonski M.E. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 100 (1993) 1297-1304
79. Toris C.B., Tafoya M.E., Camras C.B., and Yablonski M.E. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 102 (1995) 456-461
80. Toris C.B., Gleason M.L., Camras C.B., and Yablonski M.E. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol 113 (1995) 1514-1517
81. Toris C.B., Yablonski M.E., Wang Y.L., and Camras C.B. Aqueous humor dynamics in the aging human eye. Am. J. Ophthalmol 127 (1999) 407-412
82. Toris C.B., Camras C.B., and Yablonski M.E. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am. J. Ophthalmol 128 (1999) 8-14
83. Toris C.B., Zhan G.L., Wang Y.L., Zhao J., McLaughlin M.A., Camras C.B., and Yablonski M.E. Aqueous humor dynamics in monkeys with laser-induced glaucoma. J. Ocul. Pharmacol. Ther 16 (2000) 19-27
84. Toris C.B., Koepsell S.A., Yablonski M.E., and Camras C.B. Aqueous humor dynamics in ocular hypertensive patients. J. Glaucoma 11 (2002) 253-258
85. Toris C.B., Zhan G., and Camras C.B. Increase in outflow facility with unoprostone treatment in ocular hypertensive patients. Arch. Ophthalmol 122 (2004) 1782-1787
86. Townsend D.J., and Brubaker R.F. Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. Invest. Ophthalmol. Vis. Sci. 19 (1980) 256-266
87. Törnquist P. Capillary permeability in cat choroid, studied with the single injection technique (II). Acta Physiol. Scand 106 (1979) 425-430
88. Weinreb R.N., Kashiwagi K., Kashiwagi F., Tsukahara S., and Lindsey J.D. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 38 (1997) 2772-2780